NAD+vsPinealamin

Nicotinamide Adenine Dinucleotide (NAD+) is a dinucleotide coenzyme consisting of nicotinamide mononucleotide (NMN) joined to adenosine monophosphate (AMP) through a pyrophosphate bond. It exists in oxidized (NAD+) and reduced (NADH) forms and participates in over 500 enzymatic reactions, making it one of the most central molecules in cellular metabolism.

As a redox cofactor, NAD+ accepts hydride ions (H-) during catabolic reactions. In glycolysis, the TCA cycle, and fatty acid beta-oxidation, NAD+ is reduced to NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving oxidative phosphorylation and ATP production. Without adequate NAD+, the entire energy production machinery of the cell grinds to a halt.

Equally important are NAD+'s roles as a consumed substrate for three families of signaling enzymes. Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases and ADP-ribosyltransferases that use NAD+ as a co-substrate, cleaving it to nicotinamide and O-acetyl-ADP-ribose during the deacetylation reaction. SIRT1 and SIRT3 are particularly important for aging — SIRT1 deacetylates PGC-1α (activating mitochondrial biogenesis), FOXO transcription factors (activating stress resistance), and NF-κB (suppressing inflammation). SIRT3 in the mitochondrial matrix activates SOD2 and other mitochondrial enzymes. PARPs (poly-ADP-ribose polymerases) consume NAD+ during DNA damage repair, adding chains of ADP-ribose to histones near DNA breaks to recruit repair machinery. CD38, an NAD+-consuming glycohydrolase on immune cells, regulates calcium signaling and immune activation.

NAD+ levels decline 40-60% between ages 40 and 70, driven by increased CD38 expression (with chronic low-grade inflammation), increased PARP activity (from accumulated DNA damage), and reduced synthesis (decreased NAMPT enzyme activity). This decline impairs sirtuin function, reduces ATP production, compromises DNA repair, and contributes to virtually every hallmark of aging. Supplementation strategies aim to restore NAD+ levels either directly (IV infusion) or through biosynthetic precursors: NMN enters the salvage pathway one step from NAD+, while NR (nicotinamide riboside) requires an additional phosphorylation step.

Pinealamin is a low-molecular-weight peptide extract derived from the pineal glands of young cattle, processed to isolate short peptides (typically under 10 kDa) with proposed bioregulatory activity on pineal gland function. Unlike defined Khavinson tripeptides such as pinealon (Glu-Asp-Arg), pinealamin is a complex mixture of multiple peptide species, and its biological activity is attributed to the combined effect of these peptides rather than a single active component.

The proposed mechanism follows the Khavinson bioregulator framework: tissue-derived short peptides preferentially target the same tissue type from which they were extracted, binding to gene promoter regions and modulating expression of genes involved in pineal-specific functions. For pinealamin, this is hypothesised to include regulation of melatonin biosynthesis enzymes (notably AANAT and HIOMT), serotonin-to-melatonin conversion pathways, and the broader hypothalamic-pituitary-pineal axis that governs circadian rhythm.

Clinical positioning is primarily for age-related decline in melatonin secretion and associated sleep disorders in older adults — Russian observational studies have reported improvements in subjective sleep quality and measured melatonin output following pinealamin courses in middle-aged and elderly subjects. As with all Khavinson cytamins, the efficacy and mechanism evidence base sits almost entirely within Russian research traditions and has not been replicated in Western randomised controlled trials. The animal-derived sourcing also raises quality and safety considerations that vary significantly between suppliers, and pharmacopoeial standards for pinealamin do not exist outside Russian regulatory frameworks.